ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
The South African government is in discussions with Lonza and the local firm Pelchem about building a $200 million joint-venture facility that would make active pharmaceutical ingredients (APIs) for antiretroviral drugs. One goal of the venture, called Ketlaphela, is to reduce the country’s dependence on imported APIs for drugs that treat HIV and AIDS. Another is to develop downstream applications for South Africa’s fluorite reserves. Several important antiretrovirals contain fluorine. At present, state-owned Pelchem is the only South African company to make fluorochemicals.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter